Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Cresco Labs
CL
Cresco Labs
Cannabis Markets Will Battle Price Compression While Gaining Cautious Relief
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$1.50
12.2% undervalued
intrinsic discount
16 Aug
CA$1.32
Loading
1Y
-51.6%
7D
29.4%
Author's Valuation
CA$1.5
12.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$1.5
12.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-326m
848m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$547.5m
Earnings US$7.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
1.34%
Pharma revenue growth rate
1.05%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.89%
Calculation
US$7.29m
Earnings '28
x
69.36x
PE Ratio '28
=
US$505.51m
Market Cap '28
US$505.51m
Market Cap '28
/
380.28m
No. shares '28
=
US$1.33
Share Price '28
US$1.33
Share Price '28
Discounted to 2025 @ 6.89% p.a.
=
US$1.09
Fair Value '25
US$1.09
Fair Value '25
Converted to CAD @ 1.3814 USD/CAD Exchange Rate
=
CA$1.51
Fair Value '25
